US 12,259,355 B2
Microchip capillary electrophoresis assays and reagents
Timothy Riehlman, Tarrytown, NY (US); Gabriel Carreau, Tarrytown, NY (US); Jeffrey Schneiderheinze, Tarrytown, NY (US); and Nicole M. Nall, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Jul. 6, 2021, as Appl. No. 17/368,377.
Application 17/368,377 is a continuation in part of application No. 17/335,756, filed on Jun. 1, 2021.
Application 17/368,377 is a continuation in part of application No. 16/355,050, filed on Mar. 15, 2019, granted, now 11,054,389.
Application 17/335,756 is a continuation in part of application No. 16/355,050, filed on Mar. 15, 2019, granted, now 11,054,389.
Claims priority of provisional application 62/644,933, filed on Mar. 19, 2018.
Prior Publication US 2021/0333235 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 27/447 (2006.01)
CPC G01N 27/44726 (2013.01) [G01N 27/44791 (2013.01)] 24 Claims
 
1. An aqueous microchip capillary electrophoresis sample buffer for a protein drug sample, the buffer comprising:
155 to 200 mM 2-iodoacetamide;
0.50 to 1.5% lithium dodecyl sulfate; and
60 to 95 mM sodium phosphate,
wherein the aqueous microchip capillary electrophoresis sample buffer has a pH of less than or equal to 8, and wherein microchip capillary electrophoresis is used to identify contaminants in the protein drug sample.